---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-25-000030"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:37:22.397110+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mirum Q1 revenue $111.6M; raises 2025 guidance to $435-450M

## Summary
- Q1 2025 total revenue $111.6M vs $69.2M YoY, driven by LIVMARLI ($73.2M, +71%) and Bile Acid Medicines ($38.4M, +47%).
- Raises full-year 2025 revenue guidance to $435-450M from prior range.
- LIVMARLI oral tablet formulation approved by FDA; also approved in Japan for ALGS and PFIC.
- VISTAS PSC study enrollment completion expected Q3 2025; topline data Q2 2026.
- Cash and investments $298.6M as of March 31, 2025, up from $292.8M at year-end 2024.

## SEC filing metadata
- accession: 0001759425-25-000030
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000030/0001759425-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000030/mirm-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-25-000030
- JSON: https://secwatch.observer/filing/0001759425-25-000030.json
- Plain text: https://secwatch.observer/filing/0001759425-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.